Back to Journals » Lung Cancer: Targets and Therapy » Volume 5

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

Authors Weise A, Gadgeel S

Received 17 April 2014

Accepted for publication 28 April 2014

Published 6 August 2014 Volume 2014:5 Pages 35—42

DOI https://doi.org/10.2147/LCTT.S50414

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Amy M Weise, Shirish Gadgeel

Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Abstract: Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging malignancy to treat, as many patients have advanced disease at the time of diagnosis. Recent advances have led to the identification of molecularly defined subtypes of NSCLC, namely for patients with adenocarcinoma histology. The most recently identified molecular target is the anaplastic lymphoma kinase (ALK) gene rearrangement, and patient responses to the ALK inhibitor crizotinib have led to its approval in this selected patient population. Like other tyrosine kinase inhibitors, resistance to crizotinib ultimately develops by various mechanisms requiring alternative therapeutic options. This review article discusses the management of patients with the ALK gene rearrangement, mechanisms of crizotinib resistance, and future potential therapeutic options.

Keywords: non-small-cell lung cancer, disease management, cancer therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]